{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:36:09Z","timestamp":1761748569560,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T00:00:00Z","timestamp":1374278400000},"content-version":"vor","delay-in-days":1783,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.acvd.2008.09.001","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T01:32:47Z","timestamp":1226367167000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study"],"prefix":"10.1016","volume":"101","author":[{"given":"G\u00e9rard","family":"de Pouvourville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Solesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Beillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2008.09.001_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oxfordjournals.eurheartj.a015223","article-title":"The epidemiology of heart failure","volume":"18","author":"Cowie","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2008.09.001_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1388-9842(98)00008-7","article-title":"Annotated references in epidemiology","volume":"1","author":"Cowie","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2008.09.001_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0003-3928(01)80003-2","article-title":"Epidemiology of heart insufficiency","volume":"50","author":"Delahaye","year":"2001","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"10.1016\/j.acvd.2008.09.001_bib4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0735-1097(98)00634-2","article-title":"Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. \u00c9pidemiologie de l\u2019Insuffisance Cardiaque Avanc\u00e9e en Lorraine","volume":"33","author":"Zannad","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2008.09.001_bib5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00019053-200523100-00008","article-title":"Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure","volume":"23","author":"Croom","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.acvd.2008.09.001_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1388-9842(03)00112-0","article-title":"VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context","volume":"5","author":"Velazquez","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2008.09.001_bib7","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","article-title":"Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study","volume":"42","author":"Lewis","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2008.09.001_bib8","first-page":"1485","article-title":"Characteristics of patients hospitalized for myocardial infarction in France with respect to left ventricular dysfunction. Results of the USIK study","volume":"90","author":"Vaur","year":"1997","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.acvd.2008.09.001_bib9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure","volume":"22","author":"Remme","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2008.09.001_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2008.09.001_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2008.09.001_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2008.09.001_bib13","unstructured":"\u00c9chelle Nationale de Co\u00fbts et Co\u00fbts de r\u00e9f\u00e9rence 2003. http:\/\/www.atih.sante.fr (accessed May 15, 2004)."},{"key":"10.1016\/j.acvd.2008.09.001_bib14","unstructured":"\u00c9chelle priv\u00e9e en points ISAF par GHM 2001. http:\/\/www.atih.sante.fr (accessed May 15, 2004)."},{"key":"10.1016\/j.acvd.2008.09.001_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1099-1050(1998110)7:7<629::AID-HEC378>3.0.CO;2-N","article-title":"Resource costing for multinational neurologic clinical trials: methods and results","volume":"7","author":"Schulman","year":"1998","journal-title":"Health Econ"},{"key":"10.1016\/j.acvd.2008.09.001_bib16","unstructured":"French Guidelines for the economic evaluation of health care technologies. Coll\u00e8ge des \u00c9conomistes de la Sant\u00e9 http:\/\/www.ces-asso.org (September 2004 downloadable version)."},{"key":"10.1016\/j.acvd.2008.09.001_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1015371616135","article-title":"Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure","volume":"16","author":"Glick","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2008.09.001_bib18","first-page":"205","article-title":"Un essai d\u2019estimation du co\u00fbt et de l\u2019efficience de la transplantation cardiaque en France","volume":"14","author":"Sailly","year":"1996","journal-title":"Journ Economie Med"},{"key":"10.1016\/j.acvd.2008.09.001_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00019053-199711060-00007","article-title":"Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting","volume":"11","author":"Pelc","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.acvd.2008.09.001_bib20","unstructured":"Weintraub WS, Zhang Z, Kvasz M. Cost-effectiveness of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction: results from EPHESUS applied to four European countries. Annual Congress of the European Society of Cardiology. Stockholm: European Society of Cardiology;2005:Abstr P2299"},{"key":"10.1016\/j.acvd.2008.09.001_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10557-006-8282-y","article-title":"Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction \u2013 an analysis of the EPHESUS study from a Swiss perspective","volume":"20","author":"Szucs","year":"2006","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213608001198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213608001198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:34:41Z","timestamp":1761744881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213608001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1875213608001198"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2008.09.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2008.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}